

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

Test

Sample	Group	N	Result	N _{rel}
--------	-------	---	--------	------------------

Set of samples 1**(560) ANA screening (cell nucleus) - prove**

A1	(1) Fluorescent methods	>>>	65 Negative	89 %
			2 Positive	2,7 %
	(2) EIA methods	>>>	5 Negative	6,8 %
			1 Positive	1,4 %
Total per sample: n = 73		Success: 96 %		
B1	(1) Fluorescent methods		1 Negative	1,4 %
			1 Inconclusive result (borderline)	1,4 %
		>>>	65 Positive	89 %
	(2) EIA methods	>>>	6 Positive	8,2 %
Total per sample: n = 73		Success: 97 %		
Total success: 93 %				

(572) ANA screening (cell nucleus) - semi-quantity

A1	(1) Fluorescent methods	±	40 titre 0 (not measurable)	63 %
		±	19 titre 40	30 %
		±	4 titre 80	6,3 %
		±	1 titre 160	1,6 %
Total per sample: n = 64		Success (only evaluated results):	evaluation	
B1	(1) Fluorescent methods	±	1 Not specified	1,6 %
		±	1 titre 40	1,6 %
		±	4 titre 80	6,3 %
		±	7 titre 320	11 %
		±	18 titre 640	28 %
		±	25 titre 1280	39 %
		±	8 titre 2560	13 %
Total per sample: n = 64		Success (only evaluated results):	evaluation	

(561) ANA - type of fluorescence - nucleus

A1	(1) Microscopy	>>>	65 No fluorescence	98 %
			1 Unknown type of fluorescence	1,5 %
Total per sample: n = 66		Success: 98 %		
B1	(1) Microscopy		1 No fluorescence	1,5 %
			1 Fine speckled; Homogenous nucleolar pattern	1,5 %
			1 Fine speckled; Clumpy nucleolar pattern	1,5 %
		>>>	41 Homogenous nucleolar pattern	62 %
		>	19 Clumpy nucleolar pattern	29 %
			1 Clumpy nucleolar pattern; Punctate (speckled) nucleolar pattern	1,5 %
			2 Punctate (speckled) nucleolar pattern	3,0 %
Total per sample: n = 66		Success: 91 %		
Total success: 91 %				

(563) ANA screening (cytoplasm) - prove

A1	(1) Fluorescent methods		2 Negative	3,1 %
		>>>	63 Positive	97 %
Total per sample: n = 65		Success: 97 %		
B1	(1) Fluorescent methods	>>>	63 Negative	97 %
			2 Positive	3,1 %
Total per sample: n = 65		Success: 97 %		
Total success: 94 %				

(573) ANA screening (cytoplasm) - semi-quantity

A1	(1) Fluorescent methods	±	2 Not specified	3,3 %
		±	1 titre 40	1,6 %
		±	1 titre 80	1,6 %
		±	13 titre 160	21 %
		±	21 titre 320	34 %
		±	20 titre 640	33 %
		±	3 titre 1280	4,9 %
Total per sample: n = 61		Success (only evaluated results):	evaluation	
B1	(1) Fluorescent methods	±	37 titre 0 (not measurable)	61 %
		±	18 titre 40	30 %
		±	4 titre 80	6,6 %
		±	1 titre 160	1,6 %
		±	1 titre 320	1,6 %
Total per sample: n = 61		Success (only evaluated results):	evaluation	

Test		N	Result	N _{rel}
Sample	Group			
(564) ANA - type of fluorescence - cytoplasm				
A1	(1) Microscopy	2	No fluorescence	3,1 %
		1	Granular cytoplasmic pattern (mitochondria)	1,5 %
		2	Diffusion cytoplasmic picture	3,1 %
	>>>	59	Cytoskeletal patterns	91 %
		1	Unknown type of fluorescence	1,5 %
----- Total per sample: n = 65 -----		Success: 91 %		
B1	(1) Microscopy	>>>	63 No fluorescence	97 %
			1 Fine speckled cytoplasmic pattern	1,5 %
			1 Diffusion cytoplasmic picture	1,5 %
----- Total per sample: n = 65 -----		Success: 97 %		
Total success: 88 %				

Set of samples 2

(565) ANCA imunofluorescence - prove				
A2	(1) Fluorescent met. (ethanol)	>>>	41 Negative	76 %
	(2) Fluorescent met. (formalin)	>>>	7 Negative	13 %
	(99) Another measurement principle	>>>	6 Negative	11 %
----- Total per sample: n = 54 -----		Success: 100 %		
B2	(1) Fluorescent met. (ethanol)	>>>	41 Positive	76 %
	(2) Fluorescent met. (formalin)	>>>	7 Positive	13 %
	(99) Another measurement principle	>>>	6 Positive	11 %
----- Total per sample: n = 54 -----		Success: 100 %		
Total success: 100 %				

(574) ANCA IF (ethanol) - semi-quantity

A2	(0) Not specified	± 30	titre 0 (not measurable)	63 %
		± 18	titre 20	38 %
----- Total per sample: n = 48 -----		Success (only evaluated results):	evaluation	
B2	(0) Not specified	± 1	Not specified	2,1 %
		± 1	titre 20	2,1 %
		± 11	titre 80	23 %
		± 14	titre 160	29 %
		± 15	titre 320	31 %
		± 6	titre 640	13 %
----- Total per sample: n = 48 -----		Success (only evaluated results):	evaluation	

(578) ANCA IF (formalin) - semi-quantity

A2	(0) Not specified	± 25	titre 0 (not measurable)	60 %
		± 17	titre 20	40 %
----- Total per sample: n = 42 -----		Success (only evaluated results):	evaluation	
B2	(0) Not specified	± 1	Not specified	2,4 %
		± 1	titre 20	2,4 %
		± 1	titre 40	2,4 %
		± 2	titre 80	4,8 %
		± 11	titre 160	26 %
		± 19	titre 320	45 %
		± 7	titre 640	17 %
----- Total per sample: n = 42 -----		Success (only evaluated results):	evaluation	

(566) ANCA - type of fluorescence

A2	(1) Microscopy	>>>	54 No fluorescence	100 %
----- Total per sample: n = 54 -----		Success: 100 %		
B2	(1) Microscopy	>>>	54 Cytoplasmic granular fluorescence	100 %
----- Total per sample: n = 54 -----		Success: 100 %		
Total success: 100 %				

(569) anti-myeloperoxidase

A2	(2) EIA methods	>>>	51 Negative	81 %
	(5) LIA, ILMA	>>>	1 Negative	1,6 %
	(6) Immunoblotting	>>>	8 Negative	13 %
	(99) Another measurement principle	>>>	3 Negative	4,8 %
----- Total per sample: n = 63 -----		Success: 100 %		
B2	(2) EIA methods	>>>	51 Negative	81 %
	(5) LIA, ILMA	>>>	1 Negative	1,6 %
	(6) Immunoblotting	>>>	7 Negative	11 %
			1 Positive	1,6 %
	(99) Another measurement principle	>>>	3 Negative	4,8 %
----- Total per sample: n = 63 -----		Success: 98 %		
Total success: 98 %				

(570) anti-proteinase III

A2	(2) EIA methods	>>>	51 Negative	81 %
	(5) LIA, ILMA	>>>	1 Negative	1,6 %

Test					
Sample	Group		N	Result	N _{rel}
A2	(6) Immunoblotting	>>>	8	Negative	13 %
	(99) Another measurement principle	>>>	3	Negative	4,8 %
	Total per sample: n = 63		Success: 100 %		
B2	(2) EIA methods	>>>	51	Positive	81 %
	(5) LIA, ILMA	>>>	1	Positive	1,6 %
	(6) Immunoblotting	>>>	8	Positive	13 %
	(99) Another measurement principle	>>>	3	Positive	4,8 %
Total per sample: n = 63		Success: 100 %			
Total success: 100 %					

Set of samples 3**(580) Anti-ENA/SS-A/Ro-60**

A3	(2) EIA methods	>>>	35	Positive	51 %
	(5) LIA, ILMA	>>>	1	Positive	1,5 %
	(6) Immunoblotting	>>>	30	Positive	44 %
	(99) Another measurement principle	>>>	2	Positive	2,9 %
Total per sample: n = 68		Success: 100 %			
B3	(2) EIA methods	>>>	34	Negative	50 %
			1	Inconclusive result (borderline)	1,5 %
	(5) LIA, ILMA	>>>	1	Negative	1,5 %
	(6) Immunoblotting	>>>	29	Negative	43 %
	(99) Another measurement principle	>>>	1	Positive	1,5 %
Total per sample: n = 68		Success: 97 %			
Total success: 97 %					

(581) Anti-ENA/SS-B/La

A3	(2) EIA methods		1	Inconclusive result (borderline)	1,5 %
		>>>	33	Positive	49 %
	(5) LIA, ILMA	>>>	1	Positive	1,5 %
	(6) Immunoblotting		1	Inconclusive result (borderline)	1,5 %
	(99) Another measurement principle	>>>	30	Positive	44 %
Total per sample: n = 68		Success: 97 %			
B3	(2) EIA methods	>>>	34	Negative	50 %
	(5) LIA, ILMA	>>>	1	Negative	1,5 %
	(6) Immunoblotting	>>>	31	Negative	46 %
	(99) Another measurement principle	>>>	2	Negative	2,9 %
Total per sample: n = 68		Success: 100 %			
Total success: 97 %					

(582) Anti-ENA/ScI-70

A3	(2) EIA methods	>>>	34	Negative	50 %
	(5) LIA, ILMA	>>>	1	Negative	1,5 %
	(6) Immunoblotting	>>>	31	Negative	46 %
	(99) Another measurement principle	>>>	2	Negative	2,9 %
Total per sample: n = 68		Success: 100 %			
B3	(2) EIA methods	>>>	34	Negative	50 %
	(5) LIA, ILMA	>>>	1	Negative	1,5 %
	(6) Immunoblotting	>>>	31	Negative	46 %
	(99) Another measurement principle	>>>	2	Negative	2,9 %
Total per sample: n = 68		Success: 100 %			
Total success: 100 %					

(583) Anti-ENA/RNP

A3	(2) EIA methods	>>>	33	Negative	49 %
	(5) LIA, ILMA	>>>	1	Negative	1,5 %
	(6) Immunoblotting	>>>	31	Negative	46 %
	(99) Another measurement principle	>>>	2	Negative	3,0 %
Total per sample: n = 67		Success: 100 %			
B3	(2) EIA methods	>>>	33	Negative	49 %
	(5) LIA, ILMA	>>>	1	Negative	1,5 %
	(6) Immunoblotting	>>>	31	Negative	46 %
	(99) Another measurement principle	>>>	2	Negative	3,0 %
Total per sample: n = 67		Success: 100 %			
Total success: 100 %					

(584) Anti-ENA/Jo-1

A3	(2) EIA methods	>>>	34	Negative	50 %
	(5) LIA, ILMA	>>>	1	Negative	1,5 %
	(6) Immunoblotting	>>>	31	Negative	46 %
	(99) Another measurement principle	>>>	2	Negative	2,9 %

Test

Sample	Group	N	Result	N _{rel}
Total per sample: n = 68		Success: 100 %		
B3	(2) EIA methods	>>> 34	Negative	50 %
	(5) LIA, ILMA	>>> 1	Negative	1,5 %
	(6) Immunoblotting	>>> 31	Negative	46 %
	(99) Another measurement principle	>>> 2	Negative	2,9 %
Total per sample: n = 68		Success: 100 %		
Total success: 100 %				

(585) Anti-centromere antibodies

A3	(0) Not specified	>>> 5	Negative	8,9 %
	(1) Fluorescent methods	>>> 4	Negative	7,1 %
	(2) EIA methods	>>> 14	Negative	25 %
	(6) Immunoblotting	>>> 31	Negative	55 %
	(99) Another measurement principle	>>> 2	Negative	3,6 %
Total per sample: n = 56		Success: 100 %		
B3	(0) Not specified	>>> 5	Negative	8,9 %
	(1) Fluorescent methods	>>> 4	Negative	7,1 %
	(2) EIA methods	>>> 14	Negative	25 %
	(6) Immunoblotting	>>> 31	Negative	55 %
	(99) Another measurement principle	>>> 2	Negative	3,6 %
Total per sample: n = 56		Success: 100 %		
Total success: 100 %				

Set of samples 4**(588) Anti-ds-DNA immunofluores.**

A4	(1) Fluorescent methods	3	Negative	5,5 %
Total per sample: n = 55		Success: 95 %		
B4	(1) Fluorescent methods	>>> 53	Negative	96 %
		2	Positive	3,6 %
Total per sample: n = 55		Success: 96 %		
Total success: 95 %				

(577) Anti-ds-DNA immunofluor. - semi-quantity

A4	(1) Fluorescent methods	± 1	Not specified	1,9 %
		± 2	titre 0 (not measurable)	3,8 %
		± 1	titre 10	1,9 %
		± 2	titre 40	3,8 %
		± 10	titre 80	19 %
		± 11	titre 160	21 %
		± 11	titre 320	21 %
		± 8	titre 640	15 %
		± 5	titre 1280	9,6 %
		± 1	titre 2560	1,9 %
Total per sample: n = 52		Success (only evaluated results):	evaluation	
B4	(1) Fluorescent methods	± 34	titre 0 (not measurable)	65 %
		± 16	titre 10	31 %
		± 1	titre 160	1,9 %
		± 1	titre 640	1,9 %
Total per sample: n = 52		Success (only evaluated results):	evaluation	

(589) Anti-ds-DNA other methods

A4	(2) EIA methods	1	Negative	2,0 %
		>>> 36	Positive	73 %
	(5) LIA, ILMA	>>> 1	Positive	2,0 %
	(6) Immunoblotting	>>> 9	Positive	18 %
	(99) Another measurement principle	1	Negative	2,0 %
		>>> 1	Positive	2,0 %
Total per sample: n = 49		Success: 96 %		
B4	(2) EIA methods	>>> 36	Negative	73 %
		1	Positive	2,0 %
	(5) LIA, ILMA	>>> 1	Negative	2,0 %
	(6) Immunoblotting	>>> 9	Negative	18 %
	(99) Another measurement principle	>>> 1	Negative	2,0 %
		1	Positive	2,0 %
Total per sample: n = 49		Success: 96 %		
Total success: 96 %				

Summary statistics - qualitative results

(Groups: measurement principle)

EQA round: AIM2/17 - Autoimmunity

Dead line: 06.11.2017

Test

Sample	Group	N	Result	N _{rel}
--------	-------	---	--------	------------------

Set of samples 5**(591) Anti-nucleosomes IgG**

A5	(2) EIA methods	1	Inconclusive result (borderline)	2,0 %	
		>>> 35	Positive	70 %	
	(6) Immunoblotting	1	Negative	2,0 %	
		>>> 13	Positive	26 %	
----- Total per sample: n = 50 -----		Success: 96 %	-----		
B5	(2) EIA methods	>>> 36	Negative	72 %	
		(6) Immunoblotting	>>> 14	Negative	28 %
	----- Total per sample: n = 50 -----		Success: 100 %	-----	
	Total success: 96 %				

st_kl

End of report

Printed: 13.11.2017